HIT Consultant January 23, 2024
What You Should Know:
– Invitae (NYSE: NVTA), a medical genetics company, announced the completion of its sale of certain reproductive health assets, including carrier screening and non-invasive prenatal screening (NIPS), to Natera (NASDAQ: NTRA).
– The transaction is valued at up to $52.5M, comprised of cash, milestone payments, and litigation credits.
Streamlining Focus on Oncology and Rare Disease
This strategic move streamlines Invitae’s operations and allows them to focus their resources on their core strengths in clinical germline genetic information and advanced variant interpretation for oncology and rare disease patients.
“Today’s announcement further helps us streamline...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices